At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.
From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.
A meta-analysis of 39 studies found similar or slightly better cancer survival for Black veterans compared with White veterans in the VHA.
The Pediatric Cancer Research Foundation calls for systemic change as pediatric cancer creates long-term financial burdens extending through survivorship.
Fraud, waste, and abuse are key areas that can affect strategies in care delivery and can undermine the ability to give quality care.
Vaccine news shaping the 2026-2027 immunization season includes major acquisitions, a key FDA panel vote, and new data on influenza vaccine effectiveness.
OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.
FDA approves Orca-T precision Treg cell therapy for matched donor transplants, cutting chronic GVHD risk and boosting survival in blood cancers.
As CAR T-cell therapy expands into outpatient and community settings, Reimagine Care and The Center for Cancer and Blood Disorders are creating a monitoring infrastructure to support patients and caregivers alike.
Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.
NCCN added pemivibart to its lymphoma guidelines, expanding COVID-19 prevention options for immunocompromised patients.
There was no observed increase in risk to short- or mid-term clinically relevant infections despite the low levels of immunoglobulins.
House lawmakers reviewed veterans' health bills focused on mental health, rural access, spinal injury care, and military aviation research.
Experts outline what it takes to build a sustainable CGT program, from governance and SOPs to navigating complex reimbursement landscapes.
Chemo-free zanubrutinib plus rituximab in phase 3 MANGROVE cuts progression/death risk 43% vs BR for frontline mantle cell lymphoma.
New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.
Reconstructed Kaplan-Meier data benchmark durability of CAR T-cell therapy, bispecific antibodies, and zanubrutinib combos for relapsed follicular lymphoma.
The House passed HR 5347 to extend flexible Medicare ACO quality reporting and support smaller practices transitioning to digital measures.
Sheng Fu, MD, explains why patients with overlapping cardiac, renal, and metabolic disease demand new care models.
Topical delgocitinib in chronic hand eczema improves clearance and itch fast, with placebo-like safety.
New wastewater data and prior research suggest COVID-19 may follow recurring spring and summer transmission patterns, unlike influenza and RSV.
Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.
Longer sleep is linked to lower glycemic variability and reduced deviation risk in adolescents; higher daytime variability predicted shorter subsequent sleep.
Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.
Rrisankizumab is the first and only IL-23 inhibitor FDA-approved for children aged 6 and older under 40 kg with plaque psoriasis or psoriatic arthritis.
Veligrotug-vvze (Lumvoa; Viridian Therapeutics) is the first treatment for thyroid eye disease (TED) that has been approved by the FDA with labeling that includes data for both active and chronic TED.
Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida
Obesity coding gaps limit care; MCL rising in women; racial pain disparities in oncology; AML access expands; SDOH rivals genetics.
New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.
A single-center study found low rates of MRA and SGLT2 inhibitor prescribing among low-income, largely uninsured patients with heart failure.
